Extended duration of treatment with peginterferon alfa‐2a in patients with chronic hepatitis B, HBeAg‐negative and E genotype: A retrospective analysis

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Journal of Medical Virology

• Publication date

  2018-03-15

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1002/jmv.25038PMID 29384201
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection.

  2017cited by this paper
• Role of HBsAg decline in patients with chronic hepatitis B HBeAg-negative and E genotype treated with pegylated-interferon.

  2016cited by this paper
• Global , regional , and national age – sex specifi c all-cause and cause-specifi c mortality for 240 causes of death , 1990 – 2013 : a systematic analysis for the Global Burden of Disease Study 2013

  2015cited by this paper
• On‐treatment prediction of sustained response to peginterferon alfa‐2a for HBeAg‐negative chronic hepatitis B patients

  2015cited by this paper
• Role of CYP27B1+2838 promoter polymorphism in the treatment of chronic hepatitis B HBeAg negative with PEG‐interferon

  2015cited by this paper
• Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013.

  2015cited by this paper
• Different HBsAg decline after 3 years of therapy with entecavir in patients affected by chronic hepatitis B HBeAg‐negative and genotype A, D and E

  2014cited by this paper
• The E genotype of hepatitis B: clinical and virological characteristics, and response to interferon.

  2014cited by this paper
• Role of IL28-B polymorphisms in the treatment of chronic hepatitis B HBeAg-negative patients with peginterferon.

  2014cited by this paper
• Kinetics and prediction of HBsAg loss during therapy with analogues in patients affected by chronic hepatitis B HBeAg negative and genotype D

  2013cited by this paper
• Off‐therapy durability of response to entecavir therapy in hepatitis B e antigen‐negative chronic hepatitis B patients

  2013cited by this paper
• Randomised study comparing 48 and 96 weeks peginterferon α-2a therapy in genotype D HBeAg-negative chronic hepatitis B

  2012cited by this paper
• Validation of a stopping rule at week 12 using HBsAg and HBV DNA for HBeAg-negative patients treated with peginterferon alfa-2a.

  2012cited by this paper
• Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa.

  2009cited by this paper
• A Pilot Study of Extended Duration Peginterferon Alfa-2a for Patients With Hepatitis B e Antigen-Negative Chronic Hepatitis B

  2007cited by this paper
• Response to interferon alfa is hepatitis B virus genotype dependent: genotype A is more sensitive to interferon than genotype D.

  2005cited by this paper

• Current Status of Antiviral Therapy for Chronic Hepatitis B and Therapeutic Strategies for Achieving Clinical Cure of Chronic Hepatitis B

  2025cites this paper
• Prediction of cccDNA dynamics in hepatitis B patients by a combination of serum surrogate markers

  2025cites this paper
• Establishment of a multi-parameter prediction model for the functional cure of HBeAg-negative chronic hepatitis B patients treated with pegylated interferonα and decision process based on response-guided therapy strategy

  2023cites this paper
• The efficacy of pegylated interferon alpha-2a and entecavir in HBeAg-positive children and adolescents with chronic hepatitis B

  2022cites this paper
• Genotype E: The neglected genotype of hepatitis B virus

  2021cites this paper
• Extended duration therapy regimens based on Pegylated interferon for chronic hepatitis B patients focusing on hepatitis B surface antigen loss: A systematic review and meta-analysis.

  2020cites this paper
• Chronic hepatitis B genotype E in African migrants: response to nucleos(t)ide treatment in real clinical practice

  2018cites this paper